See more : Tivoli A/S (TIV.CO) Income Statement Analysis – Financial Results
Complete financial analysis of MDxHealth SA (MDXH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of MDxHealth SA, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- DRTECH Corporation (214680.KQ) Income Statement Analysis – Financial Results
- Northland Power Inc. (NPIFF) Income Statement Analysis – Financial Results
- Train Alliance Sweden AB (publ) (TRAIN-B.ST) Income Statement Analysis – Financial Results
- Blue Water Ventures International, Inc. (BWVI) Income Statement Analysis – Financial Results
- Sky Quarry Inc. (SKYQ) Income Statement Analysis – Financial Results
MDxHealth SA (MDXH)
About MDxHealth SA
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 70.19M | 37.05M | 22.24M | 18.37M | 11.79M | 28.34M | 40.51M | 29.87M | 17.47M | 11.48M | 7.55M | 4.92M | 3.48M | 3.37M | 3.65M | 4.21M | 3.85M | 3.66M | 3.65M | 525.97K |
| Cost of Revenue | 26.26M | 17.84M | 11.83M | 10.52M | 11.93M | 11.65M | 10.20M | 10.10M | 6.91M | 6.45M | 5.79M | 1.19M | 344.76K | 492.09K | 256.46K | 338.28K | 656.10K | 72.59K | 135.02K | 12.20K |
| Gross Profit | 43.93M | 19.22M | 10.41M | 7.85M | -144.00K | 16.69M | 30.31M | 19.76M | 10.56M | 5.03M | 1.76M | 3.72M | 3.14M | 2.88M | 3.39M | 3.87M | 3.19M | 3.58M | 3.51M | 513.77K |
| Gross Profit Ratio | 62.58% | 51.87% | 46.82% | 42.72% | -1.22% | 58.88% | 74.81% | 66.17% | 60.47% | 43.78% | 23.31% | 75.72% | 90.10% | 85.41% | 92.97% | 91.96% | 82.96% | 98.02% | 96.30% | 97.68% |
| Research & Development | 6.38M | 7.56M | 6.67M | 4.54M | 9.00M | 1.81M | 1.83M | -332.00K | 2.10M | 742.00K | 1.58M | 3.29M | 6.23M | 9.06M | 18.75M | 15.31M | 15.60M | 11.41M | 6.85M | 6.23M |
| General & Administrative | 23.01M | 23.54M | 5.07M | 4.15M | 5.68M | 6.19M | 5.35M | 3.95M | 2.97M | 2.50M | 1.86M | 1.80M | 6.20M | 4.98M | 5.75M | 4.33M | 3.59M | 2.50M | 1.80M | 1.40M |
| Selling & Marketing | 36.92M | 26.58M | 2.59M | 2.31M | 4.43M | 9.07M | 8.15M | 7.61M | 6.02M | 4.91M | 2.50M | 2.95M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 59.93M | 50.12M | 7.65M | 6.46M | 10.10M | 15.26M | 13.51M | 11.56M | 8.99M | 7.40M | 4.36M | 4.75M | 6.20M | 4.98M | 5.75M | 4.33M | 3.59M | 2.50M | 1.80M | 1.40M |
| Other Expenses | 4.96M | -559.00K | 22.93M | 23.97M | 23.92M | 31.71M | 27.25M | 21.39M | 13.85M | 12.22M | 11.90M | 7.46M | -93.32K | -33.25K | 0.00 | 1.39K | -77.27K | -242.84K | -72.25K | -67.78K |
| Operating Expenses | 71.26M | 57.12M | 37.25M | 34.97M | 43.03M | 48.78M | 42.58M | 32.61M | 24.94M | 20.37M | 17.83M | 15.50M | 12.34M | 14.01M | 24.50M | 19.64M | 19.25M | 14.18M | 8.72M | 7.70M |
| Cost & Expenses | 97.52M | 74.95M | 49.08M | 45.50M | 54.95M | 60.44M | 52.78M | 42.71M | 31.85M | 26.82M | 23.63M | 16.70M | 12.68M | 14.50M | 24.76M | 19.98M | 19.91M | 14.25M | 8.86M | 7.71M |
| Interest Income | 1.09M | 125.00K | 11.00K | 4.00K | 10.00K | 21.00K | 0.00 | 6.00K | 13.00K | 14.00K | 16.00K | 87.29K | 277.36K | 295.25K | 644.74K | 1.59M | 1.53M | 868.43K | 138.57K | 146.40K |
| Interest Expense | 5.58M | 6.14M | 1.88M | 1.35M | 318.00K | 82.00K | 0.00 | 0.00 | 99.00K | 23.00K | 20.00K | 357.08K | 82.95K | 113.05K | 28.65K | 12.53K | 1.61M | 1.11M | 210.82K | 214.19K |
| Depreciation & Amortization | 6.86M | 4.91M | 3.04M | 3.33M | 3.42M | 2.94M | 2.21M | 1.72M | 881.00K | 333.00K | 418.00K | 527.68K | 397.90K | 462.83K | 3.29M | 1.40M | 839.81K | 497.56K | 280.70K | 325.34K |
| EBITDA | -30.47M | -36.39M | -23.99M | -23.79M | -39.74M | -29.47M | -10.19M | -11.57M | -13.50M | -14.88M | -15.59M | -9.80M | -9.22M | -10.37M | -16.66M | -13.43M | -12.86M | -8.77M | -4.93M | -6.86M |
| EBITDA Ratio | -43.41% | -89.03% | -107.46% | -130.55% | -338.88% | -104.00% | -24.88% | -37.25% | -77.29% | -130.33% | -203.20% | -228.77% | -244.73% | -307.41% | -470.29% | -303.54% | -395.27% | -276.04% | -135.09% | -1,304.64% |
| Operating Income | -27.33M | -37.90M | -26.84M | -27.12M | -43.17M | -32.10M | -12.27M | -12.85M | -14.38M | -15.34M | -16.07M | -11.78M | -9.20M | -11.13M | -21.11M | -15.77M | -16.00M | -10.35M | -5.14M | -7.12M |
| Operating Income Ratio | -38.93% | -102.28% | -120.69% | -147.63% | -366.30% | -113.27% | -30.30% | -43.01% | -82.34% | -133.65% | -212.75% | -239.50% | -264.12% | -329.89% | -578.14% | -374.54% | -415.41% | -283.00% | -140.80% | -1,353.61% |
| Total Other Income/Expenses | -15.77M | -6.14M | -2.16M | -1.54M | -506.00K | -393.00K | -127.00K | -441.00K | -91.00K | 86.00K | -104.00K | -89.00K | 209.00K | 182.21K | 616.08K | 853.66K | 1.45M | 625.59K | -180.88K | 78.62K |
| Income Before Tax | -43.10M | -44.04M | -29.00M | -28.66M | -43.68M | -32.49M | -12.40M | -13.29M | -14.47M | -15.26M | -16.18M | -11.87M | -9.00M | -10.94M | -20.49M | -14.19M | -14.54M | -9.72M | -5.07M | -7.04M |
| Income Before Tax Ratio | -61.40% | -118.86% | -130.41% | -156.01% | -370.60% | -114.66% | -30.61% | -44.49% | -82.86% | -132.90% | -214.12% | -241.36% | -258.54% | -324.49% | -561.26% | -337.04% | -377.70% | -265.90% | -138.98% | -1,338.66% |
| Income Tax Expense | 1.00K | 6.14M | 1.88M | 1.35M | -575.00K | -41.00K | -113.00K | -113.00K | 86.00K | 9.00K | 4.00K | 91.25K | -194.41K | 31.92K | -616.08K | -1.58M | -1.61M | -1.11M | -210.82K | -214.19K |
| Net Income | -43.10M | -50.19M | -30.88M | -30.01M | -43.10M | -32.45M | -12.29M | -13.17M | -14.47M | -15.26M | -16.18M | -11.87M | -9.00M | -10.98M | -20.49M | -14.19M | -14.54M | -9.72M | -5.07M | -7.04M |
| Net Income Ratio | -61.40% | -135.45% | -138.84% | -163.33% | -365.72% | -114.51% | -30.33% | -44.11% | -82.86% | -132.90% | -214.12% | -241.36% | -258.54% | -325.43% | -561.26% | -337.04% | -377.70% | -265.90% | -138.98% | -1,338.66% |
| EPS | -1.66 | -3.16 | -2.53 | -3.61 | -6.89 | -5.63 | -2.46 | -2.86 | -3.51 | -4.39 | -5.38 | -5.38 | -5.23 | -8.32 | -15.55 | -11.98 | -13.46 | -11.33 | -11.10 | -18.76 |
| EPS Diluted | -1.66 | -3.16 | -2.53 | -3.61 | -6.89 | -5.63 | -2.46 | -2.86 | -3.51 | -4.39 | -5.38 | -5.38 | -5.23 | -8.32 | -15.55 | -11.98 | -13.46 | -11.33 | -11.10 | -18.76 |
| Weighted Avg Shares Out | 25.91M | 15.87M | 12.19M | 8.32M | 6.26M | 5.76M | 4.99M | 4.61M | 4.13M | 3.48M | 3.00M | 2.21M | 1.72M | 1.32M | 1.32M | 1.18M | 1.08M | 857.92K | 456.88K | 375.28K |
| Weighted Avg Shares Out (Dil) | 25.91M | 15.87M | 12.19M | 8.32M | 6.26M | 5.76M | 4.99M | 4.61M | 4.13M | 3.48M | 3.00M | 2.21M | 1.72M | 1.32M | 1.32M | 1.18M | 1.08M | 857.92K | 456.88K | 375.28K |
MDxHealth Announces Completion of Transition to Single Listing on Nasdaq
NEWS RELEASE – REGULATED INFORMATION DECEMBER 18, 2023, 1:00 AM ET / 07:00 AM CET MDxHealth Announces Completion of Transition to Single Listing on Nasdaq IRVINE, CA, and HERSTAL, BELGIUM – December 18, 2023 – MDxHealth SA (NASDAQ/Euronext...
MDxHealth Announces Completion of Mandatory ADS Exchange and Commencement of Transition Period to Single Listing on Nasdaq
NEWS RELEASE – REGULATED INFORMATION NOVEMBER 27, 2023, 1:00 am ET / 7:00 am CET MDxHealth Announces Completion of Mandatory ADS Exchange and Commencement of Transition Period to Single Listing on Nasdaq IRVINE, CA, and HERSTAL, BELGIUM – November 27,...
MDxHealth to Participate in the 35th Annual Piper Sandler Healthcare Conference
NEWS RELEASE November 14, 2023, 4PM ET/ 22:00 CET MDxHealth to Participate in the 35 th Annual Piper Sandler Healthcare Conference IRVINE, CA, and HERSTAL, BELGIUM – November 14, 2023 – MDxHealth SA (Nasdaq and Euronext Brussels: MDXH), a commercial-stage...
MDxHealth SA (MXDHF) Q3 2023 Earnings Call Transcript
MDxHealth SA (OTC:MXDHF) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET Company Participants Michael McGarrity - Chief Executive Officer Ron Kalfus - Chief Financial Officer Conference Call Participants Daniel Sammarco - TD Cowen Andrew Brackmann - William...
MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2023
NEWS RELEASE – REGULATED INFORMATION 8 NOVEMBER 2023, 4:00PM EDT / 22:00 CET MDxHealth Reports Results for the Third Quarter and Nine-Month Period Ended September 30, 2023 IRVINE, CA, and HERSTAL, BELGIUM – November 8, 2023 – MDxHealth...
MDxHealth Announces the Approval by its Shareholders of the Proposed Transition to a Sole Listing of Shares on Nasdaq, and Details of the Share Consolidation
NEWS RELEASE – REGULATED INFORMATION INSIDE INFORMATION NOVEMBER 6, 2023, 1:00 AM ET / 7:00 CET
MDxHealth to Present Third Quarter 2023 Financial Results and Corporate Update on November 8
NEWS RELEASE 25 OCTOBER 2023, 4PM ET / 22:00 CET MDxHealth to Present Third Quarter 2023 Financial Results and Corporate Update on November 8 Company to Host Conference Call with Live Q&A, November 8, 2023 at 4:30pm ET/ 22:30 CET...
Mdxhealth's New Share Capital Amount and New Number of Shares
NEWS RELEASE - REGULATED INFORMATION October 20, 2023 , 4:00 PM EDT / 22:00 CET
MDxHealth SA Sponsored ADR (MDXH) Expected to Beat Earnings Estimates: Should You Buy?
MDxHealth SA Sponsored ADR (MDXH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
MDxHealth Reports Preliminary Q3-2023 Revenues
NEWS RELEASE – INSIDE AND REGULATED INFORMATION 9 OCTOBER 2023, 4PM ET / 22:00 CET MDxHealth Reports Preliminary Q3-2023 Revenues IRVINE, CA, and HERSTAL, BELGIUM – October 9, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics...
Source: https://incomestatements.info
Category: Stock Reports